Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01379534
Title A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

endometrial cancer

Therapies

Dovitinib

Age Groups: senior | adult
Covered Countries USA | ITA | ESP


No variant requirements are available.